WO2022066997A1 - Recombinant microorganisms and uses therefor - Google Patents

Abstract

Provided is a genetically engineered microorganism comprising expression of multiple CoA transferases conferring certain advantages, including increased product production and fermentation stability. Also provided is a method for increasing production of a product comprising culturing the genetically engineered microorganism in the presence of a gaseous substrate wherein the gaseous substrate may comprise a C1-carbon source comprising one or more of CO, CO2, and H2.

Description

RECOMBINANT MICROORGANISMS AND USES THEREFOR

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63/083,257, filed September 25, 2020, the entirety of which is incorporated herein by reference.

FIELD

[0002] This application relates to genetically engineered microorganisms and use of those microorganisms for the fermentative production of products from substrates comprising carbon dioxide (CO2), carbon monoxide (CO), and/or hydrogen (H2).

BACKGROUND

[0003] Mitigation of impending climate change requires drastic reductions in emissions of greenhouse gases (GHGs), such as those generated through the burning of fossil fuels like coal and oil. Although sustainable sources of fuels and chemicals are currently insufficient to significantly displace our dependence on fossil carbon, gas fermentation has recently emerged as an alternative platform for the biological fixation of such gases such as CO, CO2, and/or H2 into sustainable fuels and chemicals. In particular, gas fermentation technology can utilize a wide range of feedstocks including gasified carbonaceous matter (e.g., municipal solid waste or agricultural waste) or industrial waste gases (e.g., from steel mills or oil refineries) to produce ethanol, jet fuel, and a variety of other products. Gas fermentation alone could displace 30% of crude oil use and reduce global CO2 emissions by 10%, but, as with any disruptive technology, many technical challenges must be overcome before this potential is fully achieved.

[0004] In particular, there remains a need for additional microorganisms with improved stability and substrate selectivity for the increased production of native and nonnative products from gaseous substrates.

SUMMARY

[0005] The disclosure is directed to a genetically engineered Wood-Ljungdahl microorganism comprising a first exogenous CoA transferase, and at least one additional exogenous CoA transferase. The first exogenous CoA transferase may replace a coding region of an acetolactate decarboxylase gene. The at least one additional exogenous CoA transferase may replace a coding region of an aldehyde-alcohol dehydrogenase gene. The microorganism may further comprise an exogenous thiolase and an exogenous decarboxylase selected from acetoacetate decarboxylase or alpha-ketoisovalerate decarboxylase, with the first exogenous CoA transferase. The exogenous CoA transferases may be Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB. The exogenous CoA transferases may be nonnative to the microorganism, or the exogenous CoA transferases may be native to the microorganism. The exogenous CoA transferases may be the same or the exogenous CoA transferases may be different. The exogenous CoA transferases may be under the control of both an acetolactate decarboxylase promoter and at least one other promoter. The microorganism may not produce 2,3-butanediol. The microorganism may produce one or more of acetone and isopropanol. The microorganism may further comprise a disruptive mutation in a primary-secondary alcohol dehydrogenase gene, a thioesterase gene, a 3 -hydroxybutyryl coA dehydrogenase gene, or any combination thereof. The exogenous CoA transferases may enable production of 1 -butanol, butyrate, butene, butadiene, methyl ethyl ketone, ethylene, acetone, isopropanol, lipids, 3 -hydroxypropionate, terpenes, isoprene, fatty acids, 2-butanol, 1,2-propanediol, 1 -propanol, 1 -hexanol, 1 -octanol, chori smate-derived products, 3 -hydroxybutyrate, 1,3-butanediol, 2-hydroxyisobutyrate or 2-hydroxyisobutyric acid, isobutylene, adipic acid, keto-adipic acid, 1,3 -hexanediol, 3 -methyl-2 -butanol, 2-buten- l-ol, isovalerate, isoamyl alcohol, or monoethylene glycol. The microorganism may be a Cl- fixing microorganism. The microorganism may further comprise an exogenous thiolase, an exogenous decarboxylase selected from acetoacetate decarboxylase or alpha-ketoisovalerate decarboxylase, or any combination thereof, with the at least one additional exogenous CoA transferase. The microorganism may be a bacterium. The microorganism may be a member of a genus selected from Acetobacterium, Alkalibaculum, Blautia, Butyribacterium, Clostridium, Eubacterium, Moorella, Oxobacter, Sporomusa, and Thermoanaerobacter . [0006] The disclosure is further directed to a method for increasing production of a product comprising culturing a genetically engineered Wood-Ljungdahl microorganism comprising a first exogenous CoA transferase, and at least one additional exogenous CoA transferase in the presence of a gaseous substrate. The gaseous substrate may comprise a Cl -carbon source comprising one or more of CO, CO2, CH4 and H2. The gaseous substrate may comprise syngas or industrial waste gas. The product may be one or more of acetone and isopropanol.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Fig. l is a set of graphs depicting fermentation of a microorganism with a disrupted acetolactate decarboxylase gene C^budA) and a disrupted primary-secondary alcohol dehydrogenase gene (EsecAdh). The top panel shows metabolite production (ethanol and acetate). The bottom panel shows gas consumption and production (CO, CO2, and H2).

[0008] Fig. 2 is a set of graphs depicting fermentation of a ^budA^secAdh microorganism with expression of an acetone pathway (thlA, ctfAB, adc) on a plasmid. The acetone pathway is under the control of a Pfer promoter. The top panel shows metabolite production (ethanol, acetate, and acetone). The bottom panel shows gas consumption and production (CO, CO2, and H2).

[0009] Fig. 3 is a set of graphs depicting fermentation of a EsecAdh microorganism with knock-in of an acetone pathway thlA, ctfAB, adc) at an acetolactate decarboxylase gene (hudA) locus. The acetone pathway is under the control of a PbudA promoter and a Pfer promoter. The top panel shows metabolite production (ethanol, acetate, and acetone). The bottom panel shows gas consumption and production (CO, CO2, and H2).

[0010] Fig. 4 is a set of graphs depicting fermentation of a microorganism with knock-in of an acetone pathway thlA, ctfAB, adc) at bifunctional aldehyde-alcohol dehydrogenase (adhEl+adhE2) gene locus and a functional primary-secondary alcohol dehydrogenase secAdh) gene. Primary-secondary alcohol dehydrogenase secAdh) converts acetone to isopropanol, such that this strain produces isopropanol rather than acetone. The acetone pathway is under the control of a PadhEi/E2 promoter and a Pfer promoter. The top panel shows metabolite production (ethanol, acetate, butanediol, and isopropanol). The bottom panel shows gas consumption and production (CO, CO2, and H2).

[0011] Fig. 5 is a bar graph depicting protein expression and acetone production levels of selected strains indicating generally low ctfAB expression particularly in strains with low acetone production. Metabolic modeling based on fermentation data also points to the ctfAB reaction being a limiting step in acetone/isopropanol production.

[0012] Figs. 6A-C are sets of graphs depicting a comparison of acetone and isopropanol plasmid strains in producing a desired product. The top panel shows increased acetone production in strains having an additional copy of ctfAB. The middle panel and bottom panel show increased isopropanol production in strains having an additional copy of ctfAB.

[0013] Fig. 7 is a graph depicting fermentation of a microorganism with additional expression of an acetone pathway (thlA, ctfAB, adc) on a plasmid, only additional expression ctfAB, or no additional pathway expression. The acetone pathway is under the control of a Pfer promoter. [0014] Fig. 8 is a graph depicting integrated genome strains having an additional copy of ctfAB show an improvement in isopropanol production as compared to an integrated genome strain without the additional copy of ctfAB.

[0015] Fig. 9 is a set of bar graphs depicting the effect of an additional copy of ctfAB on acetone and isopropanol production. The left panel shows continuous acetone production and the effect of an additional copy of ctfAB. The right panel shows continuous isopropanol production with different secAdh variants and the effect of an additional copy of ctfAB.

DESCRIPTION

[0016] Acetolactate decarboxylase is a key step for formation of 2,3 -butanediol (2,3-BDO) (Kbpke, Appl Env Microbiol, 80: 3394-3405, 2014) and knocking out this enzyme has been demonstrated to abolish 2,3-BDO production (WO 2013/115659). In order to channel flux towards other heterologous products such as acetone or isopropanol, a knockout of acetolactate decarboxylase would be expected to increase production of those heterologous products.

[0017] However, the inventors have found that this is not necessarily the case. In particular, the inventors have discovered that knock-in of genes responsible for the production of heterologous products at the acetolactate decarboxylase locus is key for achieving stable fermentation and high product titers.

[0018] Moreover, it was previously speculated that the thiolase reaction serves as the bottleneck in the production pathway, as the condensation of two molecules of acetyl-CoA to acetoacetyl-CoA is the thermodynamically most unfavorable step in the pathway. However, the inventors have surprisingly discovered that the downstream CoA transferase step is most critical to improve flux to the target product.

[0019] The inventors have also discovered that plasmid expression or knock-in of genes responsible for the production of heterologous products at a bifunctional aldehy de-alcohol dehydrogenase gene locus while having a functional primary-secondary alcohol dehydrogenase gene increases isopropanol production. Similarly, plasmid expression or knock-in of genes responsible for the production of heterologous products at a bifunctional aldehyde-alcohol dehydrogenase gene locus and a knock-out of the primary-secondary alcohol dehydrogenase gene increases acetone production.

[0020] Provided is a genetically engineered microorganism comprising plasmid expression or knock-in of DNA at an acetolactate decarboxylase gene locus, or at both an acetolactate decarboxylase gene locus and at an aldehyde-alcohol dehydrogenase (adhEl+adhE2) gene locus. In one embodiment, the DNA replaces the coding region of the acetolactate decarboxylase gene, either in its entirety or in part. In one embodiment, the DNA does not replace the acetolactate decarboxylase promoter. In one embodiment, DNA replaces the coding region of the acetolactate decarboxylase gene, either in its entirety or in part, and also DNA replaces the coding region of the aldehyde-alcohol dehydrogenase (adhEl+adhE2') gene, either in its entirety or in part.

[0021] In one embodiment, the acetolactate decarboxylase has the activity defined by EC 4.1.1.5, i.e., (S)-2-hydroxy-2-methyl-3-oxobutanoate

> (R)-2-acetoin + CO2. In one embodiment, the acetolactate decarboxylase is budA. In one embodiment, the budA comprises SEQ ID NO: 3.

[0022] After the knock-in is performed, the microorganism will typically not have a functional acetolactate decarboxylase gene, such that the microorganism will express acetolactate decarboxylase and will not produce products such as 2,3 -butanediol.

[0023] In one embodiment, the knocked-in DNA encodes one or more enzymes. In one embodiment, these enzyme(s) are nonnative to the microorganism, i.e., not naturally present in the microorganism. In one embodiment these enzyme(s) are native to the microorganism, i.e., naturally present in the microorganism, and simply add another copy of the enzyme(s) into the genome of the microorganism.

[0024] In one embodiment, the enzyme(s) encoded by the knocked-in DNA are under the control of an acetolactate decarboxylase promoter, e.g., PbudA. In one embodiment, the DNA comprises a promoter, such as a Pfer promoter. In one embodiment, the enzyme(s) are under the control of both an acetolactate decarboxylase promoter and at least one other promoter. In one embodiment, the enzyme(s) are under the control of both PbudA and Pfer.

[0025] In one embodiment, an acetone pathway is knocked-in at the acetolactate decarboxylase gene locus. The acetone pathway may comprise a thiolase, a CoA transferase, and a decarboxylase. In one embodiment, the decarboxylase is acetoacetate decarboxylase or alpha-ketoisovalerate decarboxylase. For example, the acetone pathway may comprise thlA, ctfAB, and adc or thlA, ctfAB, and kivd. In one embodiment, the CoA transferase is a butyrate-acetoacetate CoA transferase, an acetate CoA transferase, a succinyl-CoA transferase, a 4-hydroxybutyryl CoA transferase, a ketoadipate-succinyl CoA transferase, or a propionate CoA transferase. In one embodiment, the CoA transferase is only the ctfA subunit. In one embodiment, the CoA transferase is only the ctfB subunit. In one embodiment the pathway may comprise ctfA but not adc. In one embodiment, the pathway may comprise ctfB but not adc. If present, a primary-secondary alcohol dehydrogenase, such as secAdh, will convert acetone to isopropanol. Introduction of a disruptive mutation (e.g., a knock-out mutation) in a gene encoding this enzyme will result in the production of acetone whereas expression of this enzyme will result in the production of isopropanol. Accordingly, depending on the genetic background of the host microorganism, introduction of the acetone pathway will result in the production of either acetone or isopropanol. The engineering of microorganisms to produce acetone and isopropanol is described in WO 2012/115527. The engineering of microorganisms to knock-out primary-secondary alcohol dehydrogenase activity is described in WO 2015/085015.

[0026] In one embodiment, an acetone pathway is knocked-in at the acetolactate decarboxylase gene locus, and also knocked-in at the aldehyde-alcohol dehydrogenase gene locus. In one embodiment, an acetone pathway is knocked-in at the acetolactate decarboxylase gene locus, and only a CoA transferase is knocked-in at the aldehyde-alcohol dehydrogenase gene locus. In one embodiment, the CoA transferase is a butyrate-acetoacetate CoA transferase, an acetate CoA transferase, a succinyl-CoA transferase, a 4-hydroxybutyryl CoA transferase, or a ketoadipate-succinyl CoA transferase. The acetone pathway may comprise thlA, ctfAB, and adc or thlA, ctfAB, and kivd. If present, a primary-secondary alcohol dehydrogenase, such as secAdh, will convert acetone to isopropanol. Introduction of a disruptive mutation (e.g., a knock-out mutation) in a gene encoding this enzyme will result in the production of acetone whereas expression of this enzyme will result in the production of isopropanol. Accordingly, depending on the genetic background of the host microorganism, introduction of the acetone pathway will result in the production of either acetone or isopropanol. The engineering of microorganisms to produce acetone and isopropanol is described in WO 2012/115527. The engineering of microorganisms to knock-out primarysecondary alcohol dehydrogenase activity is described in WO 2015/085015.

[0027] In one embodiment, the microorganism comprises an acetone pathway and also comprises a disruptive mutation in primary-secondary alcohol dehydrogenase gene, such that the microorganism produces acetone. In one embodiment, the microorganism comprises an acetone pathway and also comprises a functional primary-secondary alcohol dehydrogenase, such that the microorganism produces isopropanol.

[0028] In fact, the knocked-in DNA may encode essentially any enzyme or enzyme pathway. For example, the enzyme(s) encoded by the knocked-in DNA may enable production of 1- butanol, butyrate, butene, butadiene, methyl ethyl ketone, ethylene, acetone, isopropanol, lipids, 3 -hydroxypropionate, terpenes, isoprene, fatty acids, 2-butanol, 1,2-propanediol, 1-propanol, 1-hexanol, 1-octanol, chori smate-derived products, 3 -hydroxybutyrate, 1,3-butanediol, 2-hydroxyisobutyrate or 2-hydroxyisobutyric acid, isobutylene, adipic acid, keto-adipic acid, 1,3-hexanediol, 3-methyl-2-butanol, 2-buten-l-ol, isovalerate, isoamyl alcohol, or monoethylene glycol.

[0029] In one embodiment, the energetics for the enzyme pathways illustrated that thiolase would have been expected to require an additional copy since it is the only endergonic enzyme pathway. In one embodiment, the energetics are as follows, thlA (+26 kJ/mol), ctfAB (-5.7 kJ/mol), Adc (-41.9 kJ/mol), and secAdh (-16.2 kJ/mol NADH; -17.4 kJ/mol NADPH). In one embodiment, three copies of thlA were expressed on a plasmid demonstrating minimal improvement in desired product production. Unexpectedly, the inventors discovered that the downstream CoA transferase step is most critical to improve flux to the target product.

[0030] In one embodiment, a total of 247 strains harboring distinct acetone biosynthesis pathway designs, including all possible promoter-gene combinations for the reference enzymes, were obtained and screened. In one embodiment, varying promoters led to an 11- fold improvement in production, while combining promoters and the identified unique enzyme variants, resulted in another 2-fold improvement over the best-performing design using genes from the reference strains. In one embodiment, the best-performing designs were based on thlA, ctfAB, and Adc, and moved forward to continuous fermentation testing and genome integration. In one embodiment, after optimizing the acetone pathway, a library of engineered C. autoethanogenum secAdh enzymes in was screened for conversion of acetone to isopropanol. Several variants and wild-type showed nearly complete conversion (>97%) of 20g/L of fed acetone when grown on gas and were moved forward for testing in continuous fermentation and genome integration.

[0031] In one embodiment, by simulating changes to the expression level of each enzyme associated with central metabolism and the acetone pathway, the model predicted that overexpressing ctfAB would increase flux to acetone.

[0032] In one embodiment, the microorganism is a Cl -fixing microorganism. In one embodiment, the microorganism is a Wood-Ljungdahl microorganism. In one embodiment, the microorganism is a bacterium. In one embodiment, the microorganism is a member of a genus selected from Acetobacterium, Alkalibaculum, Blautia, Butyribacterium, Clostridium, Eubacterium, Moorella, Oxobacter, Sporomusa, and Thermoanaerobacter .

[0033] Further provided is a method of increasing the production a product comprising culturing the microorganism in the presence of a gaseous substrate. In one embodiment, the gaseous substrate comprises a Cl -carbon source comprising CO, CO2, and/or H2. In one embodiment, the gaseous substrate comprises syngas or industrial waste gas. In one embodiment, the product is 1 -butanol, butyrate, butene, butadiene, methyl ethyl ketone, ethylene, acetone, isopropanol, lipids, 3 -hydroxypropionate, terpenes, isoprene, fatty acids, 2- butanol, 1,2-propanediol, 1 -propanol, 1 -hexanol, 1 -octanol, chori smate-derived products, 3 -hydroxybutyrate, 1,3-butanediol, 2-hydroxyisobutyrate or 2-hydroxyisobutyric acid, isobutylene, adipic acid, keto-adipic acid, 1,3 -hexanediol, 3-methyl-2-butanol, 2-buten-l-ol, isovalerate, isoamyl alcohol, or monoethylene glycol.

[0034] The term “fermentation” should be interpreted as a metabolic process that produces chemical changes in a substrate. For example, a fermentation process receives one or more substrates and produces one or more products through utilization of one or more microorganisms. The term “fermentation,” “gas fermentation” and the like should be interpreted as the process which receives one or more substrate, such as syngas produced by gasification and produces one or more product through the utilization of one or more Cl- fixing microorganism. Preferably the fermentation process includes the use of one or more bioreactor. The fermentation process may be described as either “batch” or “continuous”. “Batch fermentation” is used to describe a fermentation process where the bioreactor is filled with raw material, e.g. the carbon source, along with microorganisms, where the products remain in the bioreactor until fermentation is completed. In a “batch” process, after fermentation is completed, the products are extracted, and the bioreactor is cleaned before the next “batch” is started. “Continuous fermentation” is used to describe a fermentation process where the fermentation process is extended for longer periods of time, and product and/or metabolite is extracted during fermentation. Preferably the fermentation process is continuous.

[0035] The term “non-naturally occurring” when used in reference to a microorganism is intended to mean that the microorganism has at least one genetic modification not found in a naturally occurring strain of the referenced species, including wild-type strains of the referenced species. Non-naturally occurring microorganisms are typically developed in a laboratory or research facility.

[0036] The terms “genetic modification,” “genetic alteration,” or “genetic engineering” broadly refer to manipulation of the genome or nucleic acids of a microorganism by the hand of man. Likewise, the terms “genetically modified,” “genetically altered,” or “genetically engineered” refers to a microorganism containing such a genetic modification, genetic alteration, or genetic engineering. These terms may be used to differentiate a lab-generated microorganism from a naturally-occurring microorganism. Methods of genetic modification of include, for example, heterologous gene expression, gene or promoter insertion or deletion, nucleic acid mutation, altered gene expression or inactivation, enzyme engineering, directed evolution, knowledge-based design, random mutagenesis methods, gene shuffling, and codon optimization.

[0037] Metabolic engineering of microorganisms, such as Clostridia, can tremendously expand their ability to produce many important fuel and chemical molecules other than native metabolites, such as ethanol. However, until recently, Clostridia were considered genetically intractable and therefore generally off limits to extensive metabolic engineering efforts. In recent years several different methods for genome engineering for Clostridia have been developed including intron-based methods (ClosTron) (Kuehne, Strain Eng: Methods and Protocols, 389-407, 2011), allelic exchange methods (ACE) (Heap, Nucl Acids Res, 40: e59, 2012; Ng, PLoS One, 8: e56051, 2013), Triple Cross (Liew, Frontiers Microbiol, 7: 694, 2016), methods mediated through I-Scel (Zhang, Journal Microbiol Methods, 108: 49-60, 2015), MazF (Al-Hinai, Appl Environ Microbiol, 78: 8112-8121, 2012), or others (Argyros, Appl Environ Microbiol, 77: 8288-8294, 2011), Cre-Lox (Ueki, mBio, 5: e01636-01614, 2014), and CRISPR/Cas9 (Nagaraju, Biotechnol Biofuels, 9: 219, 2016). However, it remains extremely challenging to iteratively introduce more than a few genetic changes, due to slow and laborious cycling times and limitations on the transferability of these genetic techniques across species. Furthermore, we do not yet sufficiently understand Cl metabolism in Clostridia to reliably predict modifications that will maximize Cl uptake, conversion, and carbon/energy/redox flows towards product synthesis. Accordingly, introduction of target pathways in Clostridia remains a tedious and time-consuming process.

[0038] “Recombinant” indicates that a nucleic acid, protein, or microorganism is the product of genetic modification, engineering, or recombination. Generally, the term “recombinant” refers to a nucleic acid, protein, or microorganism that contains or is encoded by genetic material derived from multiple sources, such as two or more different strains or species of microorganisms.

[0039] “Wild type” refers to the typical form of an organism, strain, gene, or characteristic as it occurs in nature, as distinguished from mutant or variant forms.

[0040] “Endogenous” refers to a nucleic acid or protein that is present or expressed in the wild-type or parental microorganism from which the microorganism of the disclosure is derived. For example, an endogenous gene is a gene that is natively present in the wild-type or parental microorganism from which the microorganism of the disclosure is derived. In one embodiment, the expression of an endogenous gene may be controlled by an exogenous regulatory element, such as an exogenous promoter. [0041] “Exogenous” refers to a nucleic acid or protein that originates outside the microorganism of the disclosure. For example, an exogenous gene or enzyme may be artificially or recombinantly created and introduced to or expressed in the microorganism of the disclosure. An exogenous gene or enzyme may also be isolated from a heterologous microorganism and introduced to or expressed in the microorganism of the disclosure. Exogenous nucleic acids may be adapted to integrate into the genome of the microorganism of the disclosure or to remain in an extra-chromosomal state in the microorganism of the disclosure, for example, in a plasmid.

[0042] “Heterologous” refers to a nucleic acid or protein that is not present in the wild-type or parental microorganism from which the microorganism of the disclosure is derived. For example, a heterologous gene or enzyme may be derived from a different strain or species and introduced to or expressed in the microorganism of the disclosure. The heterologous gene or enzyme may be introduced to or expressed in the microorganism of the disclosure in the form in which it occurs in the different strain or species. Alternatively, the heterologous gene or enzyme may be modified in some way, e.g., by codon-optimizing it for expression in the microorganism of the disclosure or by engineering it to alter function, such as to reverse the direction of enzyme activity or to alter substrate specificity.

[0043] The terms “polynucleotide,” “nucleotide,” “nucleotide sequence,” “nucleic acid,” and “oligonucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.

Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise one or more modified nucleotides, such as methylated nucleotides or nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

[0044] As used herein, “expression” refers to the process by which a polynucleotide is transcribed from a DNA template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as “gene products.”

[0045] The terms “polypeptide”, “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein, the term “amino acid” includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.

[0046] “Enzyme activity,” or simply “activity,” refers broadly to enzymatic activity, including, but not limited, to the activity of an enzyme, the amount of an enzyme, or the availability of an enzyme to catalyze a reaction. Accordingly, “increasing” enzyme activity includes increasing the activity of an enzyme, increasing the amount of an enzyme, or increasing the availability of an enzyme to catalyze a reaction. Similarly, “decreasing” enzyme activity includes decreasing the activity of an enzyme, decreasing the amount of an enzyme, or decreasing the availability of an enzyme to catalyze a reaction.

[0047] “Mutated” refers to a nucleic acid or protein that has been modified in the microorganism of the disclosure compared to the wild-type or parental microorganism from which the microorganism of the disclosure is derived. In one embodiment, the mutation may be a deletion, insertion, or substitution in a gene encoding an enzyme. In another embodiment, the mutation may be a deletion, insertion, or substitution of one or more amino acids in an enzyme.

[0048] In particular, a “disruptive mutation” is a mutation that reduces or eliminates (i.e., “disrupts”) the expression or activity of a gene or enzyme. The disruptive mutation may partially inactivate, fully inactivate, or delete the gene or enzyme. The disruptive mutation may be any mutation that reduces, prevents, or blocks the biosynthesis of a product produced by an enzyme. The disruptive mutation may be a knockout (KO) mutation. The disruption may also be a knockdown (KD) mutation that reduces, but does not entirely eliminate, the expression or activity of a gene, protein, or enzyme. While KOs are generally effective in increasing product yields, they sometimes come with the penalty of growth defects or genetic instabilities that outweigh the benefits, particularly for non-growth coupled products. The disruptive mutation may include, for example, a mutation in a gene encoding an enzyme, a mutation in a genetic regulatory element involved in the expression of a gene encoding an enzyme, the introduction of a nucleic acid which produces a protein that reduces or inhibits the activity of an enzyme, or the introduction of a nucleic acid (e.g., antisense RNA, siRNA, CRISPR) or protein which inhibits the expression of an enzyme. The disruptive mutation may be introduced using any method known in the art.

[0049] Introduction of a disruptive mutation results in a microorganism of the invention that produces no target product or substantially no target product or a reduced amount of target product compared to the parental microorganism from which the microorganism of the disclosure is derived. For example, the microorganism of the disclosure may produce no target product or at least about 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% less target product than the parental microorganism. For example, the microorganism of the disclosure may produce less than about 0.001, 0.01, 0.10, 0.30, 0.50, or 1.0 g/L target product.

[0050] “Knock-in” refers to a genetic engineering method that involves the substitution of DNA in a genetic locus or the insertion of new DNA in a genetic locus. Often, a knock-in will replace a gene with one or more different genes. For instance, an acetolactate decarboxylase (budA) gene may be replaced in whole or in part with one or more different genes. In one embodiment, only the coding region of the gene is replaced. In one embodiment, the entire operon for the gene is replaced, including any promoter regions. [0051] “ Codon optimization” refers to the mutation of a nucleic acid, such as a gene, for optimized or improved translation of the nucleic acid in a particular strain or species. Codon optimization may result in faster translation rates or higher translation accuracy. In an embodiment, the genes of the disclosure are codon optimized for expression in Clostridium, particularly Clostridium autoethanogenum, Clostridium ljungdahlii, or Clostridium ragsdalei. In another embodiment, the genes of the disclosure are codon optimized for expression in Clostridium autoethanogenum LZ1561, which is deposited under DSMZ accession number DSM23693.

[0052] “Overexpressed” refers to an increase in expression of a nucleic acid or protein in the microorganism of the disclosure compared to the wild-type or parental microorganism from which the microorganism of the disclosure is derived. Overexpression may be achieved by any means known in the art, including modifying gene copy number, gene transcription rate, gene translation rate, or enzyme degradation rate.

[0053] The term “variants” includes nucleic acids and proteins whose sequence varies from the sequence of a reference nucleic acid and protein, such as a sequence of a reference nucleic acid and protein disclosed in the prior art or exemplified herein. The disclosure may be practiced using variant nucleic acids or proteins that perform substantially the same function as the reference nucleic acid or protein. For example, a variant protein may perform substantially the same function or catalyze substantially the same reaction as a reference protein. A variant gene may encode the same or substantially the same protein as a reference gene. A variant promoter may have substantially the same ability to promote the expression of one or more genes as a reference promoter.

[0054] Such nucleic acids or proteins may be referred to herein as “functionally equivalent variants.” By way of example, functionally equivalent variants of a nucleic acid may include allelic variants, fragments of a gene, mutated genes, polymorphisms, and the like. Homologous genes from other microorganisms are also examples of functionally equivalent variants. These include homologous genes in species such as Clostridium acetobutylicum, Clostridium beijerinckii. or Clostridium ljungdahlii, the details of which are publicly available on websites such as Genbank or NCBI. Functionally equivalent variants also include nucleic acids whose sequence varies as a result of codon optimization for a particular microorganism. A functionally equivalent variant of a nucleic acid will preferably have at least approximately 70%, approximately 80%, approximately 85%, approximately 90%, approximately 95%, approximately 98%, or greater nucleic acid sequence identity (percent homology) with the referenced nucleic acid. A functionally equivalent variant of a protein will preferably have at least approximately 70%, approximately 80%, approximately 85%, approximately 90%, approximately 95%, approximately 98%, or greater amino acid identity (percent homology) with the referenced protein. The functional equivalence of a variant nucleic acid or protein may be evaluated using any method known in the art.

[0055] Nucleic acids may be delivered to a microorganism of the disclosure using any method known in the art. For example, nucleic acids may be delivered as naked nucleic acids or may be formulated with one or more agents, such as liposomes. The nucleic acids may be DNA, RNA, cDNA, or combinations thereof, as is appropriate. Restriction inhibitors may be used in certain embodiments. Additional vectors may include plasmids, viruses, bacteriophages, cosmids, and artificial chromosomes. In an embodiment, nucleic acids are delivered to the microorganism of the disclosure using a plasmid. By way of example, transformation (including transduction or transfection) may be achieved by electroporation, ultrasonication, polyethylene glycol-mediated transformation, chemical or natural competence, protoplast transformation, prophage induction, or conjugation. In certain embodiments having active restriction enzyme systems, it may be necessary to methylate a nucleic acid before introduction of the nucleic acid into a microorganism.

[0056] Furthermore, nucleic acids may be designed to comprise a regulatory element, such as a promoter, to increase or otherwise control expression of a particular nucleic acid. The promoter may be a constitutive promoter or an inducible promoter. Ideally, the promoter is a Wood-Ljungdahl pathway promoter, a ferredoxin promoter, a pyruvate :ferredoxin oxidoreductase promoter, an Rnf complex operon promoter, an ATP synthase operon promoter, or a phosphotransacetylase/acetate kinase operon promoter.

[0057] A “microorganism” is a microscopic organism, especially a bacterium, archaeon, virus, or fungus. The microorganism of the disclosure is typically a bacterium. As used herein, recitation of “microorganism” should be taken to encompass “bacterium.” [0058] A “parental microorganism” is a microorganism used to generate a microorganism of the disclosure. The parental microorganism may be a naturally-occurring microorganism (i.e., a wild-type microorganism) or a microorganism that has been previously modified (i.e., a mutant or recombinant microorganism). The microorganism of the disclosure may be modified to express or overexpress one or more enzymes that were not expressed or overexpressed in the parental microorganism. Similarly, the microorganism of the disclosure may be modified to contain one or more genes that were not contained by the parental microorganism. The microorganism of the disclosure may also be modified to not express or to express lower amounts of one or more enzymes that were expressed in the parental microorganism. In one embodiment, the parental microorganism is Clostridium auloelhanogenum. Clostridium ljungdahlii, or Clostridium ragsdalei. In an embodiment, the parental microorganism is Clostridium autoethanogenum LZ1561, which was deposited with Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) located at InhoffenstraBe 7B, D-38124 Braunschweig, Germany on June 7, 2010 under the terms of the Budapest Treaty and accorded accession number DSM23693. This strain is described in International Patent Application No. PCT/NZ2011/000144, which published as WO 2012/015317.

[0059] The term “derived from” indicates that a nucleic acid, protein, or microorganism is modified or adapted from a different (e.g., a parental or wild-type) nucleic acid, protein, or microorganism, so as to produce a new nucleic acid, protein, or microorganism. Such modifications or adaptations typically include insertion, deletion, mutation, or substitution of nucleic acids or genes. Generally, the microorganism of the disclosure is derived from a parental microorganism. In one embodiment, the microorganism of the disclosure is derived from Clostridium autoethanogenum, Clostridium ljungdahlii, or Clostridium ragsdalei. In an embodiment, the microorganism of the disclosure is derived from Clostridium autoethanogenum LZ1561, which is deposited under DSMZ accession number DSM23693. [0060] The microorganism of the disclosure may be further classified based on functional characteristics. For example, the microorganism of the disclosure may be or may be derived from a Cl -fixing microorganism, an anaerobe, an acetogen, an ethanol ogen, a carboxydotroph, and/or a methanotroph. Table 1 provides a representative list of microorganisms and identifies their functional characteristics.

¹ Acetobacterium woodii can produce ethanol from fructose, but not from gas.

² It has not been investigated whether Clostridium magnum can grow on CO.

³ One strain of Moorella thermoacetica, Moorella sp. HUC22-1, has been reported to produce ethanol from gas.

⁴ It has not been investigated whether Sporomusa ovata can grow on CO.

⁵ It has not been investigated whether Sporomusa silvacetica can grow on CO.

⁶ It has not been investigated whether Sporomusa sphaeroides can grow on CO.

[0061] “Wood-Ljungdahl” refers to the Wood-Ljungdahl pathway of carbon fixation as described, e.g., by Ragsdale, Biochim Biophys Acta, 1784: 1873-1898, 2008. “Wood- Ljungdahl microorganisms” refers, predictably, to microorganisms containing the Wood- Ljungdahl pathway. Generally, the microorganism of the disclosure contains a native Wood- Ljungdahl pathway. Herein, a Wood-Ljungdahl pathway may be a native, unmodified Wood- Ljungdahl pathway or it may be a Wood-Ljungdahl pathway with some degree of genetic modification (e.g., overexpression, heterologous expression, knockout, etc.) so long as it still functions to convert CO, CO2, and/or H2 to acetyl-CoA.

[0062] “Cl” refers to a one-carbon molecule, for example, CO, CO2, CH4, or CH3OH. “Cl- oxygenate” refers to a one-carbon molecule that also comprises at least one oxygen atom, for example, CO, CO2, or CH3OH. “Cl -carbon source” refers a one carbon-molecule that serves as a partial or sole carbon source for the microorganism of the disclosure. For example, a Cl- carbon source may comprise one or more of CO, CO2, CH4, CH3OH, or CH2O2. Preferably, the Cl -carbon source comprises one or both of CO and CO2. A “Cl -fixing microorganism” is a microorganism that has the ability to produce one or more products from a Cl carbon source. Typically, the microorganism of the disclosure is a Cl -fixing bacterium. In an embodiment, the microorganism of the disclosure is derived from a Cl -fixing microorganism identified in Table 1.

[0063] An “anaerobe” is a microorganism that does not require oxygen for growth. An anaerobe may react negatively or even die if oxygen is present above a certain threshold. However, some anaerobes are capable of tolerating low levels of oxygen (e.g., 0.000001-5% oxygen). Typically, the microorganism of the disclosure is an anaerobe. In an embodiment, the microorganism of the disclosure is derived from an anaerobe identified in Table 1.

[0064] “Acetogens” are obligately anaerobic bacteria that use the Wood-Ljungdahl pathway as their main mechanism for energy conservation and for synthesis of acetyl-CoA and acetyl- CoA-derived products, such as acetate (Ragsdale, Biochim Biophys Acta, 1784: 1873-1898, 2008). In particular, acetogens use the Wood-Ljungdahl pathway as a (1) mechanism for the reductive synthesis of acetyl-CoA from CO2, (2) terminal electron-accepting, energy conserving process, (3) mechanism for the fixation (assimilation) of CO2 in the synthesis of cell carbon (Drake, Acetogenic Prokaryotes, In: The Prokaryotes, 3rd edition, p. 354, New York, NY, 2006). All naturally occurring acetogens are Cl-fixing, anaerobic, autotrophic, and non-methanotrophic. Typically, the microorganism of the disclosure is an acetogen. In an embodiment, the microorganism of the disclosure is derived from an acetogen identified in Table 1.

[0065] An “ethanologen” is a microorganism that produces or is capable of producing ethanol. Typically, the microorganism of the disclosure is an ethanologen. In an embodiment, the microorganism of the disclosure is derived from an ethanologen identified in Table 1.

[0066] An “autotroph” is a microorganism capable of growing in the absence of organic carbon. Instead, autotrophs use inorganic carbon sources, such as CO and/or CO2. Typically, the microorganism of the disclosure is an autotroph. In an embodiment, the microorganism of the disclosure is derived from an autotroph identified in Table 1.

[0067] A “carboxydotroph” is a microorganism capable of utilizing CO as a sole source of carbon and energy. Typically, the microorganism of the disclosure is a carboxydotroph. In an embodiment, the microorganism of the disclosure is derived from a carboxydotroph identified in Table 1.

[0068] A “methanotroph” is a microorganism capable of utilizing methane as a sole source of carbon and energy. In certain embodiments, the microorganism of the disclosure is a methanotroph or is derived from a methanotroph. In other embodiments, the microorganism of the disclosure is not a methanotroph or is not derived from a methanotroph.

[0069] More broadly, the microorganism of the disclosure may be derived from any genus or species identified in Table 1. For example, the microorganism may be a member of a genus selected from the group consisting of Acetobacterium, Alkalibaculum, Blautia, Butyribacterium, Clostridium, Eubacterium, Moorella, Oxobacter, Sporomusa, and Thermoanaerobacter. In particular, the microorganism may be derived from a parental bacterium selected from the group consisting of Acetobacterium woodii, Alkalibaculum bacchii, Blautia producta, Butyribacterium methylotrophicum, Clostridium aceticum, Clostridium autoethanogenum, Clostridium carboxidivorans, Clostridium coskatii, Clostridium drakei, Clostridium formicoaceticum, Clostridium ljungdahlii, Clostridium magnum, Clostridium ragsdalei, Clostridium scatologenes, Eubacterium limosum, Moorella thermautotrophica, Moorella thermoacetica, Oxobacter pfennigii, Sporomusa ovata, Sporomusa silvacetica, Sporomusa sphaeroides, and Thermoanaerobacter kivui.

[0070] In an embodiment, the microorganism of the disclosure is derived from the cluster of Clostridia comprising the species Clostridium autoethanogenum, Clostridium ljungdahlii, and Clostridium ragsdalei. These species were first reported and characterized by Abrini, Arch Microbiol, 161 : 345-351, 1994 (Clostridium autoethanogenum), Tanner, Int J System Bacterial, 43: 232-236, 1993 (Clostridium ljungdahlii), and Huhnke, WO 2008/028055 (Clostridium ragsdalei).

[0071] These three species have many similarities. In particular, these species are all Cl fixing, anaerobic, acetogenic, ethanol ogenic, and carboxydotrophic members of the genus Clostridium. These species have similar genotypes and phenotypes and modes of energy conservation and fermentative metabolism. Moreover, these species are clustered in clostridial rRNA homology group I with 16S rRNA DNA that is more than 99% identical, have a DNA G + C content of about 22-30 mol%, are gram-positive, have similar morphology and size (logarithmic growing cells between 0.5-0.7 x 3-5 pm), are mesophilic (grow optimally at 30-37 °C), have similar pH ranges of about 4-7.5 (with an optimal pH of about 5.5-6), lack cytochromes, and conserve energy via an Rnf complex. Also, reduction of carboxylic acids into their corresponding alcohols has been shown in these species (Perez, Biotechnol Bioeng, 110: 1066-1077, 2012). Importantly, these species also all show strong autotrophic growth on CO-containing gases, produce ethanol and acetate (or acetic acid) as main fermentation products, and produce small amounts of 2,3-butanediol and lactic acid under certain conditions.

[0072] However, these three species also have a number of differences. These species were isolated from different sources: Clostridium autoethanogenum from rabbit gut, Clostridium ljungdahlii from chicken yard waste, and Clostridium ragsdalei from freshwater sediment. These species differ in utilization of various sugars (e.g., rhamnose, arabinose), acids (e.g., gluconate, citrate), amino acids (e.g., arginine, histidine), and other substrates (e.g., betaine, butanol). Moreover, these species differ in auxotrophy to certain vitamins (e.g., thiamine, biotin). These species have differences in nucleic and amino acid sequences of Wood- Ljungdahl pathway genes and proteins, although the general organization and number of these genes and proteins has been found to be the same in all species (Kbpke, Curr Opin Biotechnol, 22: 320-325, 2011).

[0073] Thus, in summary, many of the characteristics of Clostridium autoethanogenum, Clostridium ljungdahlii, or Clostridium ragsdalei are not specific to that species, but are rather general characteristics for this cluster of Cl fixing, anaerobic, acetogenic, ethanol ogenic, and carboxydotrophic members of the genus Clostridium. However, since these species are, in fact, distinct, the genetic modification or manipulation of one of these species may not have an identical effect in another of these species. For instance, differences in growth, performance, or product production may be observed.

[0074] The microorganism of the disclosure may also be derived from an isolate or mutant of Clostridium autoethanogenum, Clostridium ljungdahlii, or Clostridium ragsdalei. Isolates and mutants of Clostridium autoethanogenum include JA1-1 (DSM10061) (Abrini, Arch Microbiol, 161 : 345-351, 1994), LZ1560 (DSM19630) (WO 2009/064200), and LZ1561 (DSM23693) (WO 2012/015317). Isolates and mutants of Clostridium ljungdahlii include ATCC 49587 (Tanner, Int J Syst Bacteriol, 43: 232-236, 1993), PETCT (DSM13528, ATCC 55383), ERI-2 (ATCC 55380) (US 5,593,886), C-01 (ATCC 55988) (US 6,368,819), 0-52 (ATCC 55989) (US 6,368,819), and OTA-1 (Tirado-Acevedo, Production of bioethanol from synthesis gas using Clostridium ljungdahlii, PhD thesis, North Carolina State University, 2010). Isolates and mutants of Clostridium ragsdalei include PI 1 (ATCC BAA-622, ATCC PTA-7826) (WO 2008/028055).

[0075] “ Substrate” refers to a carbon and/or energy source for the microorganism of the disclosure. Typically, the substrate is gaseous and comprises a Cl -carbon source, for example, CO, CO2, and/or CH4. Preferably, the substrate comprises a Cl -carbon source of CO or CO + CO2. The substrate may further comprise other non-carbon components, such as H2, N2, or electrons.

[0076] The substrate generally comprises at least some amount of CO, such as about 1, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mol% CO. The substrate may comprise a range of CO, such as about 20-80, 30-70, or 40-60 mol% CO. Preferably, the substrate comprises about 40-70 mol% CO (e.g., steel mill or blast furnace gas), about 20-30 mol% CO (e.g., basic oxygen furnace gas), or about 15-45 mol% CO (e.g., syngas). In some embodiments, the substrate may comprise a relatively low amount of CO, such as about 1-10 or 1-20 mol% CO. The microorganism of the disclosure typically converts at least a portion of the CO in the substrate to a product. In some embodiments, the substrate comprises no or substantially no (< 1 mol%) CO. [0077] The substrate may comprise some amount of H2. For example, the substrate may comprise about 1, 2, 5, 10, 15, 20, or 30 mol% H2. In some embodiments, the substrate may comprise a relatively high amount of H2, such as about 60, 70, 80, or 90 mol% H2. In further embodiments, the substrate comprises no or substantially no (< 1 mol%) H2.

[0078] The substrate may comprise some amount of CO2. For example, the substrate may comprise about 1-80 or 1-30 mol% CO2. In some embodiments, the substrate may comprise less than about 20, 15, 10, or 5 mol% CO2. In another embodiment, the substrate comprises no or substantially no (< 1 mol%) CO2.

[0079] Although the substrate is typically gaseous, the substrate may also be provided in alternative forms. For example, the substrate may be dissolved in a liquid saturated with a CO-containing gas using a microbubble dispersion generator. By way of further example, the substrate may be adsorbed onto a solid support.

[0080] The substrate and/or Cl -carbon source may be a waste gas obtained as a byproduct of an industrial process or from another source, such as combustion engine exhaust fumes, biogas, landfill gas, direct air capture, or from electrolysis. The substrate and/or Cl -carbon source may be syngas generated by pyrolysis, torrefaction, or gasification. In other words, carbon in waste material may be recycled by pyrolysis, torrefaction, or gasification to generate syngas which is used as the substrate and/or Cl -carbon source. The substrate and/or Cl -carbon source may be a gas comprising methane, and in certain embodiments the substrate and/or Cl -carbon source may be a non-waste gas.

[0081] In certain embodiments, the industrial process is selected from ferrous metal products manufacturing, such as a steel manufacturing, non-ferrous products manufacturing, petroleum refining, electric power production, carbon black production, paper and pulp manufacturing, ammonia production, methanol production, coke manufacturing, petrochemical production, carbohydrate fermentation, cement making, aerobic digestion, anerobic digestion, catalytic processes, natural gas extraction, cellulosic fermentation, oil extraction, industrial processing of geological reservoirs, processing fossil resources such as natural gas coal and oil, or any combination thereof. Examples of specific processing steps within an industrial process include catalyst regeneration, fluid catalyst cracking, and catalyst regeneration. Air separation and direct air capture are other suitable industrial processes. Specific examples in steel and ferroalloy manufacturing include blast furnace gas, basic oxygen furnace gas, coke oven gas, direct reduction of iron furnace top-gas, and residual gas from smelting iron. Other general examples include flue gas from fired boilers and fired heaters, such as naturel gas, oil, or coal fired boilers or heaters, and gas turbine exhaust. In these embodiments, the substrate and/or Cl -carbon source may be captured from the industrial process before it is emitted into the atmosphere, using any known method

[0082] The substrate and/or Cl -carbon source may be synthesis gas known as syngas, which may be obtained from reforming, partial oxidation, or gasification processes. Examples of gasification processes include gasification of coal, gasification of refinery residues, gasification of petroleum coke, gasification of biomass, gasification of lignocellulosic material, gasification of waste wood, gasification of black liquor, gasification of municipal solid waste, gasification of municipal liquid waste, gasification of industrial solid waste, gasification of industrial liquid waste, gasification of refuse derived fuel, gasification of sewerage, gasification of sewerage sludge, gasification of sludge from wastewater treatment, gasification of biogas such as when bigas is added to enhance gasification of another material. Examples of reforming processes include, steam methane reforming, steam naphtha reforming, reforming of natural gas, reforming of biogas, reforming of landfill gas, naphtha reforming, and dry methane reforming. Examples of partial oxidation processes include thermal and catalytic partial oxidation processes, catalytic partial oxidation of natural gas, partial oxidation of hydrocarbons. Examples of municipal solid waste include tires, plastics, and fibers such as in shoes, apparel, and textiles. Municipal solid waste may be simply landfill-type waste and may be sorted or unsorted. Examples of biomass may include lignocellulosic material and microbial biomass. Lignocellulosic material may include agriculture waste and forest waste.

[0083] The substrate and/or Cl -carbon source may be a gas stream comprising methane. Such a methane containing gas may be obtained from: fossil methane emissions such as during fracking, wastewater treatment, livestock, agriculture, and municipal solid waste landfills. It is also envisioned that the methane may be burned to produce electricity or heat and the Cl byproducts may be used as the substrate or carbon source.

[0084] The composition of the substrate may have a significant impact on the efficiency and/or cost of the reaction. For example, the presence of oxygen (O2) may reduce the efficiency of an anaerobic fermentation process. Depending on the composition of the substrate, it may be desirable to treat, scrub, or filter the substrate to remove any undesired impurities, such as toxins, undesired components, or dust particles, and/or increase the concentration of desirable components. [0085] In certain embodiments, the fermentation is performed in the absence of carbohydrate substrates, such as sugar, starch, lignin, cellulose, or hemicellulose.

[0086] The microorganism of the disclosure may be cultured with the gas stream to produce one or more products. For instance, the microorganism of the disclosure may produce or may be engineered to produce ethanol (WO 2007/117157), acetate (WO 2007/117157), 1-butanol (WO 2008/115080, WO 2012/053905, and WO 2017/066498), butyrate (WO 2008/115080), 2,3 -butanediol (WO 2009/151342 and WO 2016/094334), lactate (WO 2011/112103), butene (WO 2012/024522), butadiene (WO 2012/024522), methyl ethyl ketone (2-butanone) (WO 2012/024522 and WO 2013/185123), ethylene (WO 2012/026833), acetone (WO 2012/115527), isopropanol (WO 2012/115527), lipids (WO 2013/036147), 3- hydroxypropionate (3-HP) (WO 2013/180581), terpenes, including isoprene (WO 2013/180584), fatty acids (WO 2013/191567), 2-butanol (WO 2013/185123), 1,2- propanediol (WO 2014/036152), 1 -propanol (WO 2017/066498), 1 -hexanol (WO 2017/066498), 1-octanol (WO 2017/066498), chori smate-derived products (WO 2016/191625), 3 -hydroxybutyrate (WO 2017/066498), 1,3 -butanediol (WO 2017/066498), 2- hydroxyisobutyrate or 2-hydroxyisobutyric acid (WO 2017/066498), isobutylene (WO 2017/066498), adipic acid (WO 2017/066498), 1,3 -hexanediol (WO 2017/066498), 3-methyl- 2 -butanol (WO 2017/066498), 2-buten-l-ol (WO 2017/066498), isovalerate (WO 2017/066498), isoamyl alcohol (WO 2017/066498), and monoethylene glycol

(WO 2019/126400). In certain embodiments, microbial biomass itself may be considered a product. These products may be further converted to produce at least one component of diesel, jet fuel, and/or gasoline. Additionally, the microbial biomass may be further processed to produce a single cell protein (SCP).

[0087] A “native product” is a product produced by a genetically unmodified microorganism. For example, ethanol, acetate, and 2,3-butanediol are native products of Clostridium auloelhanogenum. Clostridium ljungdahlii, and Clostridium ragsdalei. A “non-native product” is a product that is produced by a genetically modified microorganism but is not produced by a genetically unmodified microorganism from which the genetically modified microorganism is derived.

[0088] “Selectivity” refers to the ratio of the production of a target product to the production of all fermentation products produced by a microorganism. The microorganism of the disclosure may be engineered to produce products at a certain selectivity or at a minimum selectivity. In one embodiment, a target product account for at least about 5%, 10%, 15%, 20%, 30%, 50%, or 75% of all fermentation products produced by the microorganism of the disclosure. In one embodiment, the target product accounts for at least 10% of all fermentation products produced by the microorganism of the disclosure, such that the microorganism of the disclosure has a selectivity for the target product of at least 10%. In another embodiment, the target product accounts for at least 30% of all fermentation products produced by the microorganism of the disclosure, such that the microorganism of the disclosure has a selectivity for the target product of at least 30%.

[0089] Typically, the culture is performed in a bioreactor. The term “bioreactor” includes a culture/fermentation device consisting of one or more vessels, towers, or piping arrangements, such as a continuous stirred tank reactor (CSTR), immobilized cell reactor (ICR), trickle bed reactor (TBR), bubble column, gas lift fermenter, static mixer, or other vessel or other device suitable for gas-liquid contact. In some embodiments, the bioreactor may comprise a first growth reactor and a second culture/fermentation reactor. The substrate may be provided to one or both of these reactors. As used herein, the terms “culture” and “fermentation” are used interchangeably. These terms encompass both the growth phase and product biosynthesis phase of the culture/fermentation process.

[0090] The culture is generally maintained in an aqueous culture medium that contains nutrients, vitamins, and/or minerals sufficient to permit growth of the microorganism. Preferably the aqueous culture medium is an anaerobic microbial growth medium, such as a minimal anaerobic microbial growth medium. Suitable media are well known in the art.

EXAMPLES

[0091] The following examples further illustrate the disclosure but, of course, should not be construed to limit its scope in any way.

Example 1

[0092] This example describes a EbudAEsecAdh microorganism.

[0093] Acetolactate decarboxylase is a key step for formation of 2,3 -butanediol (2,3-BDO) (Kbpke, Appl Env Microbiol, 80: 3394-3405, 2014) and knocking out this enzyme has been demonstrated to abolish 2,3-BDO production (WO 2013/115659). In order to channel flux towards other heterologous products such as acetone, a knockout of the respective budA gene was predicted to improve production.

[0094] A knock-out of budA in a strain of C. autoethanogenum that already contained a primary-secondary alcohol dehydrogenase (secAdh) gene knock-out (EsecAdh) (WO 2015/085015) to yield a EbudA EsecAdh strain. Knock-out of budA was carried out as described earlier (WO 2013/115659). [0095] Single colonies were isolated and restreaked to fresh appropriate selection plates and then screened for double crossover events. Confirmed double crossover events which had correct size of PCR product were re-streaked again to ensure plasmid loss. The correct colonies were picked into liquid medium and frozen stocks were prepared. Genotype was confirmed through whole genome sequencing and phenotype was checked through growth studies and continuous stirred tank reactor (CSTR) runs. As shown in Fig. 1, oscillations in metabolite production and gas consumption/production were observed.

Example 2

[0096] This example describes a EbudAEsecAdh microorganism that expresses an acetone pathway (thlA, ctfAB, adc) from a plasmid.

[0097] The EbudAEsecAdh microorganism of Example 1 was further modified to introduce a plasmid containing an acetone pathway (thlA, ctfAB, adc). This strain produced less acetone than a parent EsecAdh strain with the same pathway and under the same growth conditions but without the knock-out of budA. This is surprising since knock-out of budA would have been expected to redirect carbon flux from 2,3-BDO to other metabolites such as acetone and/or ethanol.

[0098] Furthermore, this strain did not grow well or demonstrate stable acetone production in a CSTR with a gas mix: 50% CO 10% EE, 30% CO2, balance N2 (Fig. 2). Again, an oscillation pattern was observed during growth: peaks and troughs of production, CO and hydrogen uptake in coordination with troughs and peaks of acetate and CO2 production.

Example 3

[0099] This example describes a EsecAdh microorganism with knock-in of an acetone pathway (thlA, ctfAB, adc) at an acetolactate decarboxylase (budA) gene locus.

[0100] The KI/KO plasmid for acetone pathway knock-in at the budA locus was constructed using the budA KO plasmid as the backbone and the acetone pathway was inserted in between the 5’ and 3’ budA KO homology arms of the budA KO plasmid. The acetone pathway contained thlA, clfAB. and adc under the control of the Pfer promoter. The complete KI/KO plasmid was assembled using GeneArt Seamless Cloning and Assembly Kit (ThermoFisher Scientific). The correct KI/KO plasmid was PCR screened and confirmed by sequencing.

[0101] The process of obtaining the KI mutant was the same as previously described in constructing the budA KO strain, yielding a EbudAEsecAdh strain with the acetone pathway introduced at the budA locus. PCR screening was carried out and colonies with correct size of PCR product were grown up, genomic DNA isolated and subjected for whole genome DNA sequencing in order to confirm the genotype.

[0102] The strain was grown in CSTR with a gas mix: 50% CO 10% H2, 30% CO2, balance N2. The strain grew well and produced high levels of acetone (Fig. 3).

Example 4

[0103] This comparative example describes a microorganism with a functional primarysecondary alcohol dehydrogenase (secAdh) and knock-in of an acetone pathway (thlA, ctfAB, adc) at a bifunctional aldehyde-alcohol dehydrogenase (adhEl+adhE2) gene locus. Primarysecondary alcohol dehydrogenase secAdh) converts acetone to isopropanol, such that this strain produces isopropanol rather than acetone.

[0104] The acetone pathway was inserted at the adhEl+adhE2 locus with similar steps as those described above. The homology arms were amplified via PCR and genotype was confirmed via sequencing.

[0105] The strain grew poorly in a CSTR and did not produce isopropanol or ethanol well (Fig. 4). It took about 6 days in the reactor to have enough cell biomass for appreciable production of ethanol and isopropanol. The fermentation was not stable over the two-week course of the experiment. Accordingly, knock-in at the adhEl+adhE2 locus does not confer the same benefits as knock-in at the budA locus.

Example 5

[0106] This example describes integration of other genes or pathways at the budA locus.

[0107] Wood-Ljungdahl microorganisms have already been engineered to produce a variety of nonnative products, including 1-butanol (WO 2008/115080, WO 2012/053905, and WO 2017/066498), butyrate (WO 2008/115080), butene (WO 2012/024522), butadiene (WO 2012/024522), methyl ethyl ketone (2-butanone) (WO 2012/024522 and WO 2013/185123), ethylene (WO 2012/026833), acetone (WO 2012/115527), isopropanol (WO 2012/115527), lipids (WO 2013/036147), 3-hydroxypropionate (3-HP) (WO 2013/180581), terpenes, including isoprene (WO 2013/180584), fatty acids (WO 2013/191567), 2-butanol (WO 2013/185123), 1,2-propanediol (WO 2014/036152), 1-propanol (WO 2017/066498), 1-hexanol (WO 2017/066498), 1-octanol (WO 2017/066498), chori smate-derived products (WO 2016/191625), 3 -hydroxybutyrate (WO 2017/066498), 1,3 -butanediol

(WO 2017/066498), 2-hydroxyisobutyrate or 2-hydroxyisobutyric acid (WO 2017/066498), isobutylene (WO 2017/066498), adipic acid (WO 2017/066498), 1,3 -hexanediol (WO 2017/066498), 3-methyl-2-butanol (WO 2017/066498), 2-buten-l-ol (WO 2017/066498), isovalerate (WO 2017/066498), isoamyl alcohol (WO 2017/066498), and monoethylene glycol (WO 2019/126400). Any of these genes or pathways could be knocked-in at the budA locus to yield a strain with improved performance.

[0108] In one embodiment, the knock-in DNA encodes a 3 -hydroxybutyrate pathway comprising, e.g., thlA and hbd. In one embodiment, the knock-in DNA encodes an alternative 3 -hydroxybutyrate pathway comprising, e.g., thlA, ctfAB, and hbd. In one embodiment, the knock-in DNA encodes a butanol pathway comprising, e.g., thlA, hbd, bed, and etfAB. In one embodiment, the knock-in DNA comprises a mevalonate pathway comprising, e.g., thlA, HMGS, and HMGR. These pathways may be under the control of one or more promoters, e.g., PbudA and/or Pf_er.

Example 6

[0109] This example describes omics and kinetic ensemble modeling guided flux optimization.

[0110] In one embodiment, proteomic measurements were conducted on eleven strains from a combinatorial library. These analyses included a collection of strains that had the same reference genes driven by different promoters with varied strengths, resulting in different acetone and 3-HB levels (Fig. 5). A total of 1916 distinct proteins were quantifiable across all strains, of which, the acetone pathway specific enzymes were abundant in all samples, falling within the top 3.2% of the dataset when ranked by median abundance. Statistical analysis showed that there were significant differences in the levels of these enzymes in all the combinatorial strains relative to the benchmark strains. Acetone production correlated well with the abundance of acetone pathway enzymes, with the lowest abundance found in the lowest producing strains. Consistently, the two subunits of ctfAB were found to have relatively lower expression levels compared to thlA an Adc, regardless of promoters used (Fig. 5). In one embodiment, the predicted flux to acetone and isopropanol was demonstrated by determining fold changes in ctfAB. In one embodiment, kinetic ensemble modeling predicted that total flux to acetone and isopropanol would increase as ctfAB expression increases.

Example 7

[OHl] This comparative example describes testing a strain having a sequence selected with promoter pWL and a ctfAB.

[0112] In one embodiment, a sequence for promoter pWL and the ctfAB was cloned into a vector and was then transformed into the best performing acetone and isopropanol strains. Growth experiments were performed to compare these strains. In one embodiment, a significant increase in desired product was seen along with a decrease in other metabolites, when an additional copy of ctfAB was present. These results were later confirmed in a CSTR, resulting in ~20g/L isopropanol (Figs. 6A-C).

Example 8

[0113] This comparative example describes testing an additional copy of the entire pathway (strain having thlA, ctfAB, and Adc).

[0114] In one embodiment, fermentation of a microorganism with additional expression of an acetone pathway (thlA, ctfAB, adc) on a plasmid, only additional expression ctfAB, or no additional pathway expression (Fig. 7). More improvement was seen in the strain that had only the additional ctfAB than in the strain with an additional copy of each pathway gene. In one embodiment this is due to selecting a promoter and ctfAB variant with a known improvement in protein abundance.

Example 9

[0115] This comparative example describes integration of an extra copy of ctfAB into the genome.

[0116] In one embodiment, after confirming the improvement with the additional ctfAB copy, the sequence was integrated into the genome. While knocking in the genes, some genes were simultaneously knocked out. These were predicted to be beneficial knock-outs for both acetone and isopropanol production. In each strain that was generated, an improvement in isopropanol production was seen, similar to the plasmid strains described previously, but without the extra copy of ctfAB. In one embodiment, integrated genome strains having an additional copy of ctfAB show an improvement in isopropanol production as compared to an integrated genome strain without the additional copy of ctfAB (Fig. 8).

Example 10

[0117] This example describes integration of an extra copy of ctfAB into the genome.

[0118] In one embodiment, omics measurements, kinetic modeling, and cell-free prototyping all suggest ctfAB as the limiting step for acetone production. It was discovered that a second copy of ctfAB by expressing the ctfAB variant and promoter combination registered the highest proteomic abundance on a plasmid in the strain, which led to a further 40% increase in acetone selectivity (Fig. 9, left panel). [0119] In one embodiment, an integrated strain led to a significant improvement in acetone selectivity and culture stability achieved with >4 weeks steady state production (Fig. 9, left panel).

[0120] In one embodiment, a variant exhibited the highest titer and stability for isopropanol production. In one embodiment integrated strain had a comparable level of performance (even with even slight improvements in selectivity after small adjustments in fermentation regime) as acetone integrated strains (Fig 9, right panel). For both acetone and isopropanol, expressing the extra copy of ctfAB further increased performance, achieving 90% selectivity (Fig 9.) at high rates of up to ~3 g/L/h with 85% gas utilization.

[0121] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein. The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement that that prior art forms part of the common general knowledge in the field of endeavor in any country.

[0122] The use of the terms “a” and “an” and “the” and similar referents in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted. The term “consisting essentially of’ limits the scope of a composition, process, or method to the specified materials or steps, or to those that do not materially affect the basic and novel characteristics of the composition, process, or method. The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the term “about” means ±20% of the indicated range, value, or structure, unless otherwise indicated.

[0123] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, any concentration range, percentage range, ratio range, integer range, size range, or thickness range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. [0124] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.

[0125] Embodiments of this disclosure are described herein. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the disclosure to be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.

[0126] In a first embodiment the disclosure is directed to a genetically engineered Wood- Ljungdahl microorganism comprising a first exogenous CoA transferase, and at least one additional exogenous CoA transferase.

[0127] The microorganism of the first embodiment, wherein the first exogenous CoA transferase replaces a coding region of an acetolactate decarboxylase gene.

[0128] The microorganism of the first embodiment, wherein the at least one additional exogenous CoA transferase replaces a coding region of an aldehyde-alcohol dehydrogenase gene.

[0129] The microorganism of the first embodiment, further comprising an exogenous thiolase and an exogenous decarboxylase selected from acetoacetate decarboxylase or alphaketoisovalerate decarboxylase, with the first exogenous CoA transferase.

[0130] The microorganism of the first embodiment, further comprising an exogenous thiolase and an exogenous decarboxylase selected from acetoacetate decarboxylase or alphaketoisovalerate decarboxylase, or any combination thereof.

[0131] The microorganism of the first embodiment, further comprising an exogenous thiolase and an exogenous decarboxylase selected from acetoacetate decarboxylase or alphaketoisovalerate decarboxylase, or any combination thereof, wherein the exogenous thiolase and the exogenous decarboxylase selected from acetoacetate decarboxylase or alpha- ketoisoval erate decarboxylase, or any combination thereof, function with the first exogenous CoA transferase or function with the least one additional exogenous CoA transferase.

[0132] The microorganism of the first embodiment, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB.

[0133] The microorganism of the first embodiment, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB, and wherein the exogenous CoA transferases are nonnative to the microorganism.

[0134] The microorganism of the first embodiment, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB, and wherein the exogenous CoA transferases are native to the microorganism.

[0135] The microorganism of the first embodiment, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB, and, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB wherein the exogenous CoA transferases are the same.

[0136] The microorganism of the first embodiment, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB wherein the exogenous CoA transferases are different.

[0137] The microorganism of the first embodiment, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB wherein the exogenous CoA transferases are under the control of both an acetolactate decarboxylase promoter and at least one other promoter.

[0138] The microorganism of the first embodiment, wherein the microorganism does not produce 2,3 -butanediol.

[0139] The microorganism of the first embodiment, wherein the microorganism produces one or more of acetone and isopropanol.

[0140] The microorganism of the first embodiment, further comprising a disruptive mutation in a primary-secondary alcohol dehydrogenase gene, a thioesterase gene, a 3 -hydroxybutyryl coA dehydrogenase gene, or any combination thereof.

[0141] The microorganism of the fist embodiment wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB, and wherein the exogenous CoA transferases enable production of 1 -butanol, butyrate, butene, butadiene, methyl ethyl ketone, ethylene, acetone, isopropanol, lipids, 3- hydroxypropionate, terpenes, isoprene, fatty acids, 2-butanol, 1,2-propanediol, 1 -propanol, 1-hexanol, 1-octanol, chori smate-derived products, 3 -hydroxybutyrate, 1,3 -butanediol, 2- hydroxyisobutyrate or 2-hydroxyisobutyric acid, isobutylene, adipic acid, keto-adipic acid, 1,3 -hexanediol, 3-methyl-2-butanol, 2-buten-l-ol, isovalerate, isoamyl alcohol, or monoethylene glycol.

[0142] The microorganism of the first embodiment, wherein the microorganism is a Cifixing microorganism.

[0143] The microorganism of the first embodiment, further comprising an exogenous thiolase, an exogenous decarboxylase selected from acetoacetate decarboxylase or alphaketoisovalerate decarboxylase, or any combination thereof, with the at least one additional exogenous CoA transferase.

[0144] The microorganism of the first embodiment, further comprising an exogenous thiolase, an exogenous decarboxylase selected from acetoacetate decarboxylase or alphaketoisovalerate decarboxylase, or any combination thereof.

[0145] The microorganism of the first embodiment, wherein the microorganism is a bacterium.

[0146] The microorganism of the first embodiment, wherein the microorganism is a member of a genus selected from Acetobacterium, Alkalibaculum, Blautia, Butyribacterium, Clostridium, Eubacterium, Moorella, Oxobacter, Sporomusa, or Thermoanaerobacter .

[0147] A method for increasing production of a product comprising culturing the microorganism of the first embodiment in the presence of a gaseous substrate.

[0148] The method for increasing production of a product comprising culturing the microorganism of the first embodiment in the presence of a gaseous substrate, wherein the gaseous substrate comprises a Cl -carbon source comprising one or more of CO, CO2, and H2.

[0149] The method for increasing production of a product comprising culturing the microorganism of the first embodiment in the presence of a gaseous substrate, wherein the gaseous substrate comprises syngas or industrial waste gas.

[0150] The method for increasing production of a product comprising culturing the microorganism of the first embodiment in the presence of a gaseous substrate, wherein the product is one or more of acetone and isopropanol.

Claims

CLAIMS:

1. A genetically engineered Wood-Ljungdahl microorganism comprising a first exogenous CoA transferase, and at least one additional exogenous CoA transferase.

2. The microorganism of claim 1, wherein the first exogenous CoA transferase replaces a coding region of an acetolactate decarboxylase gene.

3. The microorganism of claim 1, wherein the at least one additional exogenous CoA transferase replaces a coding region of an aldehyde-alcohol dehydrogenase gene.

4. The microorganism of claim 1, further comprising an exogenous thiolase and an exogenous decarboxylase selected from acetoacetate decarboxylase or alpha-ketoisovalerate decarboxylase, or any combination thereof.

5. The microorganism of claim 4, wherein the exogenous thiolase and the exogenous decarboxylase selected from acetoacetate decarboxylase or alpha-ketoisovalerate decarboxylase, or any combination thereof, function with the first exogenous CoA transferase or function with the least one additional exogenous CoA transferase.

6. The microorganism of claim 1, wherein the exogenous CoA transferases are Clostridium acetobutylicum CtfA and CtfB, or Clostridium beijerinckii CtfA and CtfB.

7. The microorganism of claim 6, wherein the exogenous CoA transferases are nonnative to the microorganism.

8. The microorganism of claim 6, wherein the exogenous CoA transferases are native to the microorganism.

9. The microorganism of claim 6, wherein the exogenous CoA transferases are the same.

10. The microorganism of claim 6, wherein the exogenous CoA transferases are different.

11. The microorganism of claim 6, wherein the exogenous CoA transferases are under the control of both an acetolactate decarboxylase promoter and at least one other promoter.

12. The microorganism of claim 1, wherein the microorganism does not produce 2,3- butanediol.

13. The microorganism of claim 1, wherein the microorganism produces one or more of acetone and isopropanol.

32

14. The microorganism of claim 1, further comprising a disruptive mutation in a primarysecondary alcohol dehydrogenase gene, a thioesterase gene, a 3 -hydroxybutyryl coA dehydrogenase gene, or any combination thereof.

15. The microorganism of claim 6, wherein the exogenous CoA transferases enable production of 1 -butanol, butyrate, butene, butadiene, methyl ethyl ketone, ethylene, acetone, isopropanol, lipids, 3 -hydroxypropionate, terpenes, isoprene, fatty acids, 2-butanol, 1,2- propanediol, 1 -propanol, 1 -hexanol, 1 -octanol, chori smate-derived products,

3 -hydroxybutyrate, 1,3-butanediol, 2-hydroxyisobutyrate or 2-hydroxyisobutyric acid, isobutylene, adipic acid, keto-adipic acid, 1,3 -hexanediol, 3-methyl-2-butanol, 2-buten-l-ol, isovalerate, isoamyl alcohol, or monoethylene glycol.

16. The microorganism of claim 1, wherein the microorganism is a Cl -fixing microorganism.

17. The microorganism of claim 1, wherein the microorganism is a bacterium.

18. The microorganism of claim 1, wherein the microorganism is a member of a genus selected from Acetobacterium, Alkalibaculum, Blautia, Butyribacterium, Clostridium, Eubacterium, Moorella, Oxobacter, Sporomusa, or Thermoanaerobacter .

19. A method for increasing production of a product comprising culturing the microorganism of claim 1 in the presence of a gaseous substrate.

20. The method of claim 19, wherein the gaseous substrate comprises a Cl -carbon source comprising one or more of CO, CO2, and H2.

21. The method of claim 19, wherein the gaseous substrate comprises syngas or industrial waste gas.

22. The method of claim 19, wherein the product is one or more of acetone and isopropanol.

33